Skip to content
Main Menu
Corporate
About Femasys
Who we are
Leadership
Investor Relations
Overview
News
Events & Presentations
Stock Info
Financials
Governance
Resources
Resources
Contact Us
Contact Femasys
Join Us
Healthcare Professionals
Infertility
FemaSeed
FemVue
Birth Control
Cancer Diagnosis
Patients
Infertility
FemVue
FemaSeed
Birth Control
Cancer Diagnosis
Search
Search
Resources
Find the latest news about Femasys, including our media mentions, scientific publications, and more.
All
2025
2024
2023
Video
01/30/2025
Disrupting Stagnant Women’s Reproductive Health Ecosystem with Safer More Accessible Options with Kathy Lee-Sepsick Femasys
Empowered Patient Podcast
01/30/2025
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
GlobeNewswire
01/16/2025
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
GlobeNewswire
12/03/2024
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
GlobeNewswire
11/26/2024
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
GlobeNewswire
11/20/2024
Innovation in Women’s Reproductive Health is More Important than Ever
Medical Design & Development
Load More
01/30/2025
Disrupting Stagnant Women’s Reproductive Health Ecosystem with Safer More Accessible Options with Kathy Lee-Sepsick Femasys
Empowered Patient Podcast
01/30/2025
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
GlobeNewswire
01/16/2025
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
GlobeNewswire
12/03/2024
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
GlobeNewswire
11/26/2024
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
GlobeNewswire
11/20/2024
Innovation in Women’s Reproductive Health is More Important than Ever
Medical Design & Development
11/05/2024
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment
Femtech Insider
09/09/2024
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
GlobeNewswire
08/30/2024
Femasys secures CE mark certification for FemVue MINI solution
Medical Device Network
Load More
12/15/2023
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
GlobeNewswire
11/30/2023
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
GlobeNewswire
11/28/2023
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
GlobeNewswire
11/15/2023
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
GlobeNewswire
04/13/2023
FemCerv®: Well-designed technology that can minimize patient discomfort
MDedge
02/22/2023
The Post-Roe Fertility Journey
SXSW
Load More
08/12/2022
VIDEO: President and CEO, Kathy Lee-Sepsick speaks to connecting with the audience
YouTube
08/12/2022
VIDEO: President and CEO, Kathy Lee-Sepsick at SLS
YouTube
07/28/2022
VIDEO: Femasys KOL Event
YouTube
Media Kits
For additional information, please email
[email protected]
Corporate Kit
Infertility Kit
Contraception Kit
Biopsy Kit
Main Menu
Corporate
About Femasys
Who we are
Leadership
Investor Relations
Overview
News
Events & Presentations
Stock Info
Financials
Governance
Resources
Resources
Contact Us
Contact Femasys
Join Us
Healthcare Professionals
Infertility
FemaSeed
FemVue
Birth Control
Cancer Diagnosis
Patients
Infertility
FemVue
FemaSeed
Birth Control
Cancer Diagnosis
